108
Z. Liu and Y. Liu
33. Li F, Lu J, Liu J, Liang C, Wang M, Wang L, Li D, Yao H, Zhang Q, Wen J, Zhang ZK,
Li J, Lv Q, He X, Guo B, Guan D, Yu Y, Dang L, Wu X, Li Y, Chen G, Jiang F, Sun S,
Zhang BT, Lu A, Zhang G (2017) A water-soluble nucleolin aptamer-paclitaxel conjugate for
tumor-specific targeting in ovarian cancer. Nat Commun 8(1):1390
34. Huang YF, Shangguan D, Liu H, Phillips JA, Zhang X, Chen Y, Tan W (2009) Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells.
ChemBioChem 10(5):862–868
35. Yang Q, Deng Z, Wang D, He J, Zhang D, Tan Y, Peng T, Wang XQ, Tan W (2020) Conjugating
aptamer and mitomycin C with reductant-responsive linker leading to synergistically enhanced
anticancer effect. J Amer Chem Soc 142(5):2532–2540
36. Xiong H, Yan J, Cai S, He Q, Wen N, Wang Y, Hu Y, Peng D, Liu Y, Liu Z (2020) Aptamerpyropheophorbide a conjugates with tumor spheroid targeting and penetration abilities for
photodynamic therapy. Mol Pharmaceut 17(8): 2882–2890
37. Wang R, Zhu G, Mei L, Xie Y, Ma H, Ye M, Qing FL, Tan W (2014) Automated modular
synthesis of aptamer-drug conjugates for targeted drug delivery. J Am Chem Soc 136(7):2731–
2734
38. Kuai H, Zhao Z, Mo L, Liu H, Hu X, Fu T, Zhang X, Tan W (2017) Circular bivalent aptamers
enable in vivo stability and recognition. J Am Chem Soc 139(27):9128–9131
39. Zhou F, Wang P, Peng Y, Zhang P, Huang Q, Sun W, He N, Fu T, Zhao Z, Fang X, Tan W (2019)
Molecular engineering-based aptamer-drug conjugates with accurate tunability of drug ratios
for drug combination targeted cancer therapy. Angew Chem Int Ed Engl 58(34):11661–11665
40. Zhou J, Neff CP, Swiderski P, Li H, Smith DD, Aboellail T, Remling-Mulder L, Akkina R,
Rossi JJ (2013) Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically
synthesized aptamer with a sticky bridge. Mol Ther 21(1):192–200
41. Zheng J, Zhao S, Yu X, Huang S, Liu HY (2017) Simultaneous targeting of CD44 and
EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth.
Theranostics 7(5):1373–1388
42. Liu HY, Yu X, Liu H, Wu D, She JX (2016) Co-targeting EGFR and survivin with a bivalent
aptamer-dual siRNA chimera effectively suppresses prostate cancer. Scient Rep 6:30346
43. Zhou J, Satheesan S, Li H, Weinberg MS, Morris KV, Burnett JC, Rossi JJ (2015) Cell-specific
RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits
HIV-1 infectivity. Chem Biol 22(3):379–390
44. Li J, Wang W, Sun D, Chen J, Zhang PH, Zhang JR, Min Q, Zhu JJ (2013) Aptamerfunctionalized silver nanoclusters-mediated cell type-specific siRNA delivery and tracking.
Chem Sci 4(9):3514–3521
45. Shieh YA, Yang SJ, Wei MF, Shieh MJ (2010) Aptamer-based tumor-targeted drug delivery
for photodynamic therapy. ACS Nano 4(3):1433–1442. https://doi.org/10.1021/nn901374b
46. Zhu G, Zheng J, Song E, Donovan M, Zhang K, Liu C, Tan W (2013) Self-assembled, aptamertethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc
Natl Acad Sci USA 110(20):7998–8003
47. Yazdian-Robati R, Ramezani M, Jalalian SH, Abnous K, Taghdisi SM (2016) Targeted
delivery of epirubicin to cancer cells by polyvalent aptamer system in vitro and in vivo.
Pharm Res 33(9):2289–2297
48. Xu Z, Ni R, Chen Y (2019) Targeting breast cancer stem cells by a self-assembled, aptamerconjugated DNA nanotrain with preloading doxorubicin. Int J Nanomed 14:6831–6842
49. Wei H, Leng W, Song J, Liu C, Willner MR, Huang Q, Zhou W, Vikesland PJ (2019) Realtime monitoring of ligand exchange kinetics on gold nanoparticle surfaces enabled by hot
spot-normalized surface-enhanced raman scattering. Environ Sci Technol 53(2):575–585
50. Wang X, Wang X, Bai X, Yan L, Liu T, Wang M, Song Y, Hu G, Gu Z, Miao Q, Chen
C (2019) Nanoparticle ligand exchange and its effects at the nanoparticle-cell membrane
interface. Nano Lett 19(1):8–18
51. Park J-e, Seo M, Jang E, Kim H, Kim JS, Park SJ (2019) Vesicle-like assemblies of ligandstabilized nanoparticles with controllable membrane composition and properties. Nanoscale
11(4):1837–1846
Z. Liu and Y. Liu
33. Li F, Lu J, Liu J, Liang C, Wang M, Wang L, Li D, Yao H, Zhang Q, Wen J, Zhang ZK,
Li J, Lv Q, He X, Guo B, Guan D, Yu Y, Dang L, Wu X, Li Y, Chen G, Jiang F, Sun S,
Zhang BT, Lu A, Zhang G (2017) A water-soluble nucleolin aptamer-paclitaxel conjugate for
tumor-specific targeting in ovarian cancer. Nat Commun 8(1):1390
34. Huang YF, Shangguan D, Liu H, Phillips JA, Zhang X, Chen Y, Tan W (2009) Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells.
ChemBioChem 10(5):862–868
35. Yang Q, Deng Z, Wang D, He J, Zhang D, Tan Y, Peng T, Wang XQ, Tan W (2020) Conjugating
aptamer and mitomycin C with reductant-responsive linker leading to synergistically enhanced
anticancer effect. J Amer Chem Soc 142(5):2532–2540
36. Xiong H, Yan J, Cai S, He Q, Wen N, Wang Y, Hu Y, Peng D, Liu Y, Liu Z (2020) Aptamerpyropheophorbide a conjugates with tumor spheroid targeting and penetration abilities for
photodynamic therapy. Mol Pharmaceut 17(8): 2882–2890
37. Wang R, Zhu G, Mei L, Xie Y, Ma H, Ye M, Qing FL, Tan W (2014) Automated modular
synthesis of aptamer-drug conjugates for targeted drug delivery. J Am Chem Soc 136(7):2731–
2734
38. Kuai H, Zhao Z, Mo L, Liu H, Hu X, Fu T, Zhang X, Tan W (2017) Circular bivalent aptamers
enable in vivo stability and recognition. J Am Chem Soc 139(27):9128–9131
39. Zhou F, Wang P, Peng Y, Zhang P, Huang Q, Sun W, He N, Fu T, Zhao Z, Fang X, Tan W (2019)
Molecular engineering-based aptamer-drug conjugates with accurate tunability of drug ratios
for drug combination targeted cancer therapy. Angew Chem Int Ed Engl 58(34):11661–11665
40. Zhou J, Neff CP, Swiderski P, Li H, Smith DD, Aboellail T, Remling-Mulder L, Akkina R,
Rossi JJ (2013) Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically
synthesized aptamer with a sticky bridge. Mol Ther 21(1):192–200
41. Zheng J, Zhao S, Yu X, Huang S, Liu HY (2017) Simultaneous targeting of CD44 and
EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth.
Theranostics 7(5):1373–1388
42. Liu HY, Yu X, Liu H, Wu D, She JX (2016) Co-targeting EGFR and survivin with a bivalent
aptamer-dual siRNA chimera effectively suppresses prostate cancer. Scient Rep 6:30346
43. Zhou J, Satheesan S, Li H, Weinberg MS, Morris KV, Burnett JC, Rossi JJ (2015) Cell-specific
RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits
HIV-1 infectivity. Chem Biol 22(3):379–390
44. Li J, Wang W, Sun D, Chen J, Zhang PH, Zhang JR, Min Q, Zhu JJ (2013) Aptamerfunctionalized silver nanoclusters-mediated cell type-specific siRNA delivery and tracking.
Chem Sci 4(9):3514–3521
45. Shieh YA, Yang SJ, Wei MF, Shieh MJ (2010) Aptamer-based tumor-targeted drug delivery
for photodynamic therapy. ACS Nano 4(3):1433–1442. https://doi.org/10.1021/nn901374b
46. Zhu G, Zheng J, Song E, Donovan M, Zhang K, Liu C, Tan W (2013) Self-assembled, aptamertethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc
Natl Acad Sci USA 110(20):7998–8003
47. Yazdian-Robati R, Ramezani M, Jalalian SH, Abnous K, Taghdisi SM (2016) Targeted
delivery of epirubicin to cancer cells by polyvalent aptamer system in vitro and in vivo.
Pharm Res 33(9):2289–2297
48. Xu Z, Ni R, Chen Y (2019) Targeting breast cancer stem cells by a self-assembled, aptamerconjugated DNA nanotrain with preloading doxorubicin. Int J Nanomed 14:6831–6842
49. Wei H, Leng W, Song J, Liu C, Willner MR, Huang Q, Zhou W, Vikesland PJ (2019) Realtime monitoring of ligand exchange kinetics on gold nanoparticle surfaces enabled by hot
spot-normalized surface-enhanced raman scattering. Environ Sci Technol 53(2):575–585
50. Wang X, Wang X, Bai X, Yan L, Liu T, Wang M, Song Y, Hu G, Gu Z, Miao Q, Chen
C (2019) Nanoparticle ligand exchange and its effects at the nanoparticle-cell membrane
interface. Nano Lett 19(1):8–18
51. Park J-e, Seo M, Jang E, Kim H, Kim JS, Park SJ (2019) Vesicle-like assemblies of ligandstabilized nanoparticles with controllable membrane composition and properties. Nanoscale
11(4):1837–1846